Ascentage Pharma
AAPG
6 hedge funds and large institutions have $5.21M invested in Ascentage Pharma in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.07% more ownership
Funds ownership: 0% → 0.07% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$3.03M |
| 2 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
+$482K |
| 3 |
XC
XY Capital
Central,
Hong Kong
|
+$446K |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$303K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$188K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIM
1
Monashee Investment Management
Boston,
Massachusetts
| $3.51M | +$3.03M | +159,942 | New |
|
|
PD
2
Point72 (DIFC)
Dubai,
United Arab Emirates
| $558K | +$482K | +25,404 | New |
|
|
XC
3
XY Capital
Central,
Hong Kong
| $516K | +$446K | +23,505 | New |
|
|
4
Voloridge Investment Management
Jupiter,
Florida
| $350K | +$303K | +15,943 | New |
|
|
5
Verition Fund Management
Greenwich,
Connecticut
| $218K | +$188K | +9,922 | New |
|
6
UBS Group
Zurich,
Switzerland
| $54.4K | +$47K | +2,478 | New |
|
AAPG Hedge Fund Activity: Q1 2025 in Review
6 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Ascentage Pharma (AAPG) for Q1 2025, worth a combined $5.21M.
Buyers outnumbered sellers: 6 funds opened new AAPG positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $3.03M.
- 6 institutional investors held Ascentage Pharma (AAPG) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $5.21M of Ascentage Pharma stock for Q1 2025.
- 6 funds opened new Ascentage Pharma positions in Q1 2025 and 0 closed out, a net change of +6 holders.
- The largest Ascentage Pharma buyer in Q1 2025 was Monashee Investment Management, an estimated $3.03M added.
Based on aggregated 13F filings for Q1 2025.